Rasagiline Tablets 1.0 mg (Rasagiline Mesylate)

Adult dose

This medicine is administered orally to adults once daily as monotherapy or adjunctive therapy. 1) Monotherapy or adjunctive therapy to a dopamine agonist: Administer 1 mg orally once daily. 2) Adjunctive therapy to levodopa: The recommended starting dose in patients taking levodopa is 0.5 mg once daily. If well tolerated and the clinical response is insufficient, the dose may be increased to 1 mg once daily. This medicine may be taken with or without food.

This medication should not be used in patients who are allergic to its active ingredient or other components. Additionally, it should not be administered to patients who are currently taking or have discontinued other MAO inhibitors or certain natural medicines within the last 2 weeks, as well as those taking certain pain relievers or central nervous system medications. It is generally safer not to use this medication in patients with moderate to severe liver impairment. When taking this medication, various side effects may occur, including headaches, dizziness, nausea, insomnia, joint pain, skin rash, and changes in blood pressure. Particularly, symptoms such as psychiatric disturbances, movement disorders, changes in blood pressure (either rise or fall), and drowsiness may occur, necessitating caution. This medication has a high potential for drug interactions, particularly with MAO inhibitors, certain antidepressants, pain relievers, and cold medications, so it is essential to consult healthcare professionals. Women who are pregnant or breastfeeding should be cautious when taking this medication, and its safety in pediatric patients has not been established. Elderly patients generally do not require dosage adjustments, but this may vary according to individual health status. In cases of overdose, serious side effects may occur, so strict adherence to dosages is necessary, and if overdose is suspected, immediate medical attention should be sought. When storing, it should be kept out of reach of children, and maintained at appropriate temperatures (1-25 degrees Celsius), avoiding transfer to other containers.

• influenza
• skin cancer
• leukopenia
• allergy
• decreased appetite
• depression
• hallucination
• headache
• cerebrovascular accident
• conjunctivitis

This medication should be stored in a tightly sealed container to prevent air or moisture entry, and it is best kept in a cool place between 1 and 25 degrees Celsius. Proper storage helps maintain the medication's efficacy for a longer time.

Appearance

White or almost white flat round tablets with edges

Package unit

30 tablets/box [(10 tablets/PTP x 3)], 30 tablets/bottle